Rapala VMC Corporation, Inside Information, November 14, 2025 at 10:25 a.m. EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing for the ...
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025.
Diamond Hill Investment Group, Inc. (Nasdaq: DHIL) today reported unaudited financial results for the third quarter of 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback